Non-targeted metabolomic biomarkers and metabotypes of type 2 diabetes: A cross-sectional study of PREDIMED trial participants
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
AIM To characterize the urinary metabolomic fingerprint and multi-metabolite signature associated with type 2 diabetes (T2D), and to classify the population into metabotypes related to T2D. METHODS A metabolomics analysis using the 1H-NMR-based, non-targeted metabolomic approach was conducted to determine the urinary metabolomic fingerprint of T2D compared with non-T2D participants in the PREDIMED trial. The discriminant metabolite fingerprint was subjected to logistic regression analysis and ROC analyses to establish and to assess the multi-metabolite signature of T2D prevalence, respectively. Metabotypes associated with T2D were identified using the k-means algorithm. RESULTS A total of 33 metabolites were significantly different (P<0.05) between T2D and non-T2D participants. The multi-metabolite signature of T2D comprised high levels of methylsuccinate, alanine, dimethylglycine and guanidoacetate, and reduced levels of glutamine, methylguanidine, 3-hydroxymandelate and hippurate, and had a 96.4% AUC, which was higher than the metabolites on their own and glucose. Amino-acid and carbohydrate metabolism were the main metabolic alterations in T2D, and various metabotypes were identified in the studied population. Among T2D participants, those with a metabotype of higher levels of phenylalanine, phenylacetylglutamine, p-cresol and acetoacetate had significantly higher levels of plasma glucose. CONCLUSION The multi-metabolite signature of T2D highlights the altered metabolic fingerprint associated mainly with amino-acid, carbohydrate and microbiota metabolism. Metabotypes identified in this patient population could be related to higher risk of long-term cardiovascular events and therefore require further studies. Metabolomics is a useful tool for elucidating the metabolic complexity and interindividual variation in T2D towards the development of stratified precision nutrition and medicine. Trial registration at www.controlled-trials.com: ISRCTN35739639.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet
Estruch, R., Ros, E., Salas-Salvadó, J., Covas, M.-I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1200303 · Cited by 4,257
Self-citationRetractedHost-gut microbiota metabolic interactions
Nicholson, J. K., Holmes, E., Kinross, J., Burcelin, R., Gibson, G., Jia, W., & Pettersson, S. (2012) · Science · doi:10.1126/science.1223813 · Cited by 4,760
Effects of a Mediterranean-Style Diet on Cardiovascular Risk Factors: A Randomized Trial
Estruch, R., Martínez-González, M. Á., Corella, D., Salas-Salvadó, J., Ruiz-Gutiérrez, V., Covas, M. I., Fiol, M., Gómez-Gracia, E., López-Sabater, M. C., Vinyoles, E., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-1-200607040-00004 · Cited by 1,704 · cited 1×
“Validated questionnaires 110 were employed to record physical activity, lifestyle, disease history and medication use [15].”
MethodSelf-citation2. Classification and Diagnosis of Diabetes
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s005 · Cited by 1,603
Prevention of Diabetes With Mediterranean Diets: A Subgroup Analysis of a Randomized Trial
Salas-Salvadó, J., Bulló, M., Estruch, R., Ros, E., Covas, M.-I., Ibarrola-Jurado, N., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1725 · Cited by 650
Self-citationSteroid metabolomic disease signature of nonsyndromic childhood obesity
Gawlik, A., Shmoish, M., Hartmann, M. F., Malecka-Tendera, E., Wudy, S. A., & Hochberg, Z. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1754 · Cited by 36
Cited by
Small molecule metabolites: discovery of biomarkers and therapeutic targets
Qiu, S., Cai, Y., Yao, H., Lin, C., Xie, Y., Tang, S., & Zhang, A. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01399-3 · Cited by 884
A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic Receptors
Nemet, I., Saha, P. P., Gupta, N., Zhu, W., Romano, K. A., Skye, S. M., Cajka, T., Mohan, M. L., Li, L., Wu, Y., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.016 · Cited by 784
Martín-Peláez, S., Fito, M., & Castaner, O. (2020) · Nutrients · doi:10.3390/nu12082236 · Cited by 330
“For example, a reduction in the excretion of the microbial metabolites hippurate, PAG and p-cresol, as well as trigonelline and 3-hydroxymandelate, has been observed in T2D patients [97].”
BackgroundGuo, P., Furnary, T., Vasiliou, V., Yan, Q., Nyhan, K., Jones, D. P., Johnson, C. H., & Liew, Z. (2022) · Environment International · doi:10.1016/j.envint.2022.107159 · Cited by 145
Zheng, X., Zhang, W., Wan, X., Lv, X., Lin, P., Si, S., Xue, F., Wang, A., & Cao, Y. (2024) · BMC Nutrition · doi:10.1186/s40795-024-00836-y · Cited by 44
“…Mediterranean diet affects glucagon ‐ like peptide 1 [42], oxyntomodulin [43], postprandial lipemia [44], and antioxidant/ antioxidant enzymes compounds [45], gut microbiota composition and function [46, 47], branched chain aminoacid management [48] and many other aspects have certain significance.”
Background
Metadata
- Authors
- Urpi-Sarda, M., Almanza-Aguilera, E., Llorach, R., Vázquez-Fresno, R., Estruch, R., Corella, D., Sorli, J. V., Carmona, F., Sanchez-Pla, A., Salas-Salvadó, J., & Andres-Lacueva, C.
- Venue
- Diabetes & Metabolism
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 45
- Issue
- 2
- Pages
- 167-174
- ISSN
- 1262-3636 (ISSN-L)
- OpenAlex
- W2790799311
- Cited by
- 84
- References
- 6
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Non-targeted metabolomic biomarkers and metabotypes of type 2 diabetes: A cross-sectional study of PREDIMED trial participants. https://app.cochat.ai/papers/10.1016/j.diabet.2018.02.006
- The paper
- Urpi-Sarda, M., Almanza-Aguilera, E., Llorach, R., Vázquez-Fresno, R., Estruch, R., Corella, D., Sorli, J. V., Carmona, F., Sanchez-Pla, A., Salas-Salvadó, J., & Andres-Lacueva, C. (2019). Non-targeted metabolomic biomarkers and metabotypes of type 2 diabetes: A cross-sectional study of PREDIMED trial participants. Diabetes & Metabolism. https://doi.org/10.1016/j.diabet.2018.02.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.